The Effect of Niacin Administration on Oxidative Stress in Patients With Hypercholesterolmia, as Measured by the Use of a Novel Biomarker

Status

UNKNOWN

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01071525

Enrollment

Registered

2010-02-19

Start date

2010-04-30

Completion date

2010-10-31

Last updated

2010-03-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypercholesterolemia

Brief summary

1. Treatment of Hypercholesterolemic patients with niacin will cause a significant decrease in oxidative stress and a decrease in the atherogenecity in blood samples of the patients. 2. A possible correlation between oxidative stress in hypercholesterolemic patients taking niacin to clinical hypercholesterolemia parameters is possible. 3. Using a novel biomarker will enable a precise detection of the change in the oxidative stress in hypercholesterolemic patients.

Interventions

DRUGNiacin\Laropiprant

Hypercholesterolemic patients with low HDL will receive Niacin\\Laropiprant

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Hypercholesterolemia, * age above eighteen

Exclusion criteria

* Treatment with fibrates, * Pregnant/Breast feeding women

Design outcomes

Primary

Measure	Time frame
Effect on oxidative stress	three months

Countries

Israel

Contacts

Primary ContactShadi Hamoud, Dr

s_hamoud@rambam.health.gov.il+972-523591876

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026